FDA clears iView Therapeutics IND application to start trial of TRPM8 agonist, IVW-1001

News
Article

The transient receptor potential melastatin 8 (TRPM8) are cold-sensitive thermoreceptors that play central role in tear film homeostasis.

Woman with one inflamed eye Image Credit: AdobeStock/MyOceanstudio

Image Credit: AdobeStock/MyOceanstudio

iView Therapeutics announced the US Food and Drug Administration (FDA) cleared the company’s Investigational New Drug (IND) application for the initiation of a Phase 1/2 clinical trial as “safe to proceed.”1

The trial will evaluate the safety, efficacy, and tolerability of IVW-1001, a novel TRPM8 agonist, to treat signs and symptoms of dry eye diseases (DED). iView plans to move into Phase 1/2 clinical trials in the second quarter of 2024.

Houman Hemmati, MD, PhD, Chief Medical Advisor, and head of the clinical development of IVW-1001 said, “This investigational TRPM8 agonist represents an innovative approach in the treatment of dry eye diseases, a condition that challenges millions worldwide. FDA’s clearance of the IND is a critical milestone in our commitment to addressing the unmet needs of these patients through innovative science and targeted therapeutic development. We look forward to the possibility of advancing care in this important area.”1

The transient receptor potential melastatin 8 (TRPM8) are cold-sensitive thermoreceptors that play a central role in tear film homeostasis. IVW-1001 is applied over the upper eyelid and stimulates TRPM8 located in the eyelid margin, sending a perception of coolness that reduces ocular discomfort and efferent signals for increased tear secretion may also be activated.2

IVW-1001 is part of the cryosims series of compounds created by Edward T. Wei, PhD, who also earlier identified and named the cooling molecule known as icilin. Cryosims have a sufficient duration of action and evoke the full spectrum of cooling from cool, cold, frigid cold, to noxious cold.

IVW-1001 has previously shown a short duration of action and improvement in key signs and symptom relief in an Investigator Sponsored Clinical Trial. It was able to increase tear production within 5-20 minutes of administration and longer lasting effects after 2 weeks of administration. This benefit was not accompanied by any adverse events.3

References:
  1. iView Therapeutics Inc. Announced FDA’s Clearance of IND Application for IVW-1001 Ophthalmic Eyelid Wipe to Treat Signs and Symptoms of Dry Eye Disease. Press release; March 11, 2024. Accessed March 12, 2024. https://www.iviewtherapeutics.com/news/iView-Therapeutics-Inc.-Announced-FDA%E2%80%99s-Clearance-of-IND-Application-for-IVW-1001-Ophthalmic-Eyelid-Wipe-to-Treat-Signs-and-Symptoms-of-Dry-Eye-Disease
  2. R&D. iView Therapeutics. Accessed March 12, 2024. https://www.iviewtherapeutics.com/researchAndDevelopment
  3. Dry Eye. iView Therapeutics. Accessed March 12, 2024. https://www.iviewtherapeutics.com/researchAndDevelopment/IVW-1001
Recent Videos
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO; Brianna Rhue, OD, FAAO, FSLS; Ben Casella, OD; and Ben Gaddie, OD, FAAO shared their insights from the conference.
Agatha Sleboda, OD; Arti Shah, OD, FAAO; and Kent J. Nozacki, OD provide the best tips that they give to their patients during natural disasters events in light of the recent Greater Los Angeles wildfires.
Optometrists local to the Los Angeles area overview their efforts to continue providing support to patients affected by January's wildfires.
Brianna Rhue, OD, FAAO, FSLS, reviewed key takeaways from The Future of Myopia Management: Perspectives from Leading Experts talk from SECO 2025.
Dr. Nate Lighthizer shares key takeaways from the SECO Showcase on anterior segment technology and full laser certification course offered at SECO.
Dr Ben Gaddie chats about his dry eye presentation at SECO and ocular surface disease.jpg
Robert L. Stamper, MD, overviews his optometric track talk titled Objective Perimetry - Can you see it? at this year's Glaucoma 360 meeting.
Yvonne Ou, MD, outlined lifestyle modifications for glaucoma management that have proven beneficial, including yoga and cycling.
Robert L. Stamper, MD, weighs in on what he think more optometrists should know about glaucoma and current misconceptions concerning glaucoma testing.
© 2025 MJH Life Sciences

All rights reserved.